Patents by Inventor Mark Sleeman

Mark Sleeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250129366
    Abstract: The present disclosure generally relates to the treatment of subjects having liver disease or metabolic disorder or at risk of developing liver disease or metabolic disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and/or a Folliculin (FLCN) inhibitor to the subject.
    Type: Application
    Filed: August 28, 2024
    Publication date: April 24, 2025
    Inventors: Luca Andrea Lotta, George Hindy, Viktoria Gusarova, Mark Sleeman, Rene Christian Adam
  • Patent number: 12269889
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: April 8, 2025
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 12250931
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized PNPLA3 locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized PNPLA3 locus express a human PNPLA3 protein or a chimeric PNPLA3 protein, fragments of which are from human PNPLA3. Methods are provided for using such non-human animals comprising a humanized PNPLA3 locus to assess in vivo efficacy of human-PNPLA3-targeting reagents such as nuclease agents designed to target human PNPLA3.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: March 18, 2025
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Xiping Cheng, Jose F. Rojas, Mark Sleeman
  • Publication number: 20250075216
    Abstract: The present disclosure generally relates to the treatment of subjects having muscle disorder or at risk of developing muscle disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and/or a Folliculin (FLCN) inhibitor to the subject.
    Type: Application
    Filed: August 28, 2024
    Publication date: March 6, 2025
    Inventors: Luca Andrea Lotta, George Hindy, Viktoria Gusarova, Mark Sleeman, Rene Christian Adam
  • Publication number: 20240117031
    Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: April 11, 2024
    Inventors: Justin HAMILTON, Mark SLEEMAN
  • Patent number: 11780915
    Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: October 10, 2023
    Assignee: MONASH UNIVERSITY
    Inventors: Justin Hamilton, Mark Sleeman
  • Publication number: 20230192874
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 22, 2023
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 11498970
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: November 15, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Publication number: 20210227812
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized PNPLA3 locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized PNPLA3 locus express a human PNPLA3 protein or a chimeric PNPLA3 protein, fragments of which are from human PNPLA3. Methods are provided for using such non-human animals comprising a humanized PNPLA3 locus to assess in vivo efficacy of human-PNPLA3-targeting reagents such as nuclease agents designed to target human PNPLA3.
    Type: Application
    Filed: January 27, 2021
    Publication date: July 29, 2021
    Inventors: Xiping Cheng, Jose F. Rojas, Mark Sleeman
  • Publication number: 20210179707
    Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.
    Type: Application
    Filed: September 11, 2018
    Publication date: June 17, 2021
    Inventors: Justin HAMILTON, Mark SLEEMAN
  • Publication number: 20200247896
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 6, 2020
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 10640566
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 5, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Publication number: 20190144552
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 16, 2019
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 10233250
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 19, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Publication number: 20170129960
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: January 25, 2017
    Publication date: May 11, 2017
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 9587029
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 7, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Publication number: 20150337045
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: August 7, 2015
    Publication date: November 26, 2015
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 9127068
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 8, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Publication number: 20130344538
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Application
    Filed: August 30, 2013
    Publication date: December 26, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 8545847
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: October 1, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp